Douglas L. Jennings, PharmD, FACC, FAHA, FCCP, FHFSA, BCPS

Talking Therapeutics

Another Win for GLP-1 Receptor Agonists: Treatment for Patients With Diabetes and CKD

06/06/2024

Douglas L. Jennings , PharmD, FACC, FAHA, FCCP, FHFSA, BCPS;

In this week's installment of Talking Therapeutics, Dr Jennings explores a new trial that evaluates the impact of GLP-1 agonists on kidney and cardiovascular endpoints in patients with diabetes and chronic kidney disease.

In this week's installment of...

06/06/2024

Pharmacy Learning Network

Talking Therapeutics

When it Comes to COVID-19 Vaccines, Is Three a Crowd?

07/28/2021

Douglas L. Jennings , PharmD, FACC, FAHA, FCCP, FHFSA, BCPS;

In this week’s issue of Talking Therapeutics, Dr Jennings explores data regarding third-dose boosters for COVID-19 vaccines, emphasizing the importance of addressing inequities in vaccine access before developing new boosters.

In this week’s issue of Talking...

07/28/2021

Pharmacy Learning Network

Talking Therapeutics

DOACs Do-si-do Around Dementia in Patients With Atrial Fibrillation

03/24/2022

Douglas L. Jennings , PharmD, FACC, FAHA, FCCP, FHFSA, BCPS;

This week, Dr Jennings highlights new data indicating the use of direct oral anticoagulants could lower the incidence of dementia in older patients with atrial fibrillation.

This week, Dr Jennings...

03/24/2022

Pharmacy Learning Network

Talking Therapeutics

Evaluating Ivermectin as a COVID-19 Therapeutic

10/27/2022

Douglas L. Jennings , PharmD, FACC, FAHA, FCCP, FHFSA, BCPS;

In the latest installment of Talking Therapeutics, Dr Jennings shares a randomized study in which patients with mild to moderate cases of COVID-19 were treated with either ivermectin or placebo.

In the latest installment of...

10/27/2022

Pharmacy Learning Network

Talking Therapeutics

The End of the Aspirin Era in Left Ventricular Assist Devices

11/16/2023

Douglas L. Jennings , PharmD, FACC, FAHA, FCCP, FHFSA, BCPS;

In this week’s issue, Dr Jennings discusses the ARIES-HM3 trial, which explores the inclusion of aspirin with a vitamin-K antagonist for prosthetic heart valves.

In this week’s issue, Dr...

11/16/2023

Pharmacy Learning Network

Talking Therapeutics

Putting the I Back in the Lipid Lowering Team

10/13/2021

Douglas L. Jennings , PharmD, FACC, FAHA, FCCP, FHFSA, BCPS;

In this week’s issue of Talking Therapeutics, Dr Jennings highlights inclisirin, and discusses whether this novel agent holds the key to lowering residual cardiovascular risk.

In this week’s issue of Talking...

10/13/2021

Pharmacy Learning Network

Talking Therapeutics

Achieving Victory Over Venous Thromboembolism: Reviewing CHEST Guidelines

06/09/2022

Douglas L. Jennings , PharmD, FACC, FAHA, FCCP, FHFSA, BCPS;

Dr Jennings reviews key points from the second update to guidelines for the treatment of venous thromboembolism.

Dr Jennings reviews key points...

06/09/2022

Pharmacy Learning Network

Talking Therapeutics

One Small Cup of Coffee for Man, One Giant Pot for Mankind?

03/27/2023

Douglas L. Jennings , PharmD, FACC, FAHA, FCCP, FHFSA, BCPS;

Dr Jennings walks through a new study in which researchers investigated the short-term impacts of coffee consumption on healthy adult participants.

Dr Jennings walks through a new...

03/27/2023

Pharmacy Learning Network

Talking Therapeutics

Signal for Cardiovascular Harm With Triple Inhaler Therapy

03/01/2024

Douglas L. Jennings , PharmD, FACC, FAHA, FCCP, FHFSA, BCPS;

In this installment of Talking Therapeutics, Dr Jennings reviews cardiovascular harm with triple inhaler therapy for patients with chronic obstructive pulmonary disorder (COPD).

In this installment of Talking...

03/01/2024

Pharmacy Learning Network

Talking Therapeutics

Blood Pressure Potpourri

04/14/2021

Douglas L. Jennings , PharmD, FACC, FAHA, FCCP, FHFSA, BCPS;

When combining the high prevalence of hypertension with new aggressive treatment targets, a lot of patients may face the risk of having to take numerous drugs. In this week’s issue of Talking Therapeutics, Dr Jennings looks at a few recent...

When combining the high...

04/14/2021

Pharmacy Learning Network